EUVIMEDEUVIMED entdecken
Open Access

Rapid COJEC without myeloablative therapy for high‐risk neuroblastoma

Brian H Kushner iD, Ellen M Basu, Fiorella Iglesias Cardenas, Kim Kramer, Shakeel Modak iD

International Journal of Cancer · 2025

DOI: 10.1002/ijc.70043 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Brian H Kushner und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Hauptthemen laut MEDLINE: Neuroblastoma, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Arnold J. Jacobs Pediatric Cancer Fund, Band of Parents Foundation, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myeloablative therapy (MAT) is included in high‐risk neuroblastoma (HR‐NB) treatment programs of the Children's Oncology Group (COG) and the Societe Internationale d'Oncologie Pediatrique Europe Neuroblastoma (SIOPEN), but not at Memorial Sloan Kettering Cancer Center (MSK). COG and SIOPEN programs achieved 3–5‐year event‐free survival rates of ~50%–60%, similar to the MSK experience without MAT which involved patients treated with COG or MSK induction and anti‐G D2 mAb murine‐3F8 + granulocyte‐macrophage colony‐stimulating factor (GM‐CSF). We now present the first report on rapid COJEC without MAT. This retrospective study covers HR‐NB patients who received rapid COJEC but not MAT and had no prior progressive disease (PD) when referred to MSK during the era of availability of anti‐G D2 mAb naxitamab. The 28 subjects were diagnosed 1/2017–6/2023. Post‐COJEC, 10 had no distant disease (Group 1) and 18 had persistence of metastases (Group 2). Group 1 patients had resection of primary tumors and received 1–2 cycles of HR‐NB regimens (cyclophosphamide‐topotecan ± vincristine), local radiotherapy, and naxitamab + GM‐CSF; 9 also received anti‐NB vaccine. All 10 remain event‐free at median 3.5+ years post‐diagnosis. Group 2 patients received second‐line therapy post‐COJEC, including high‐dose cyclophosphamide + topotecan ± vincristine or cyclophosphamide + doxorubicin + vincristine. Treatment after all chemotherapy included naxitamab + GM‐CSF ± irinotecan‐temozolomide. Thirteen received vaccine. Twelve remain relapse‐free at median 2.4+ years post‐diagnosis, including 3 who developed secondary neoplasms—myelodysplastic syndrome ( n = 2, successfully treated) or thyroid carcinoma. Six developed PD (four are again in complete remission and two died of NB). Avoiding MAT after rapid COJEC does not appear to adversely affect outcome compared to rapid COJEC + MAT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuroblastomaAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleRetrospective StudiesInfantChild, PreschoolGranulocyte-Macrophage Colony-Stimulating FactorChildAntibodies, MonoclonalImmunoglobulin GAntibodies, Monoclonal, Murine-Derived

Stichwörter der Autor:innen

COJECimmunotherapyneuroblastoma

Substanzen

Granulocyte-Macrophage Colony-Stimulating Factor3F8 antibodyAntibodies, MonoclonalImmunoglobulin GAntibodies, Monoclonal, Murine-Derived

Autor:innen und Institutionen

  • Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

ORCID-Profile: Brian H Kushner, Shakeel Modak

Förderung

  • Arnold J. Jacobs Pediatric Cancer Fund
  • Band of Parents Foundation
  • NCI NIH HHS
  • Katie's Find A Cure Fund
  • Robert Steel Foundation
  • Rhyan Loos Family Fund
  • Robert K Steel Family Foundation
  • National Cancer Institute

Zitieren

APA

Kushner, B. H., Basu, E. M., Cardenas, F. I., Kramer, K., & Modak, S. (2025). Rapid COJEC without myeloablative therapy for high‐risk neuroblastoma. International Journal of Cancer. https://doi.org/10.1002/ijc.70043

Vancouver

Kushner BH, Basu EM, Cardenas FI, Kramer K, Modak S. Rapid COJEC without myeloablative therapy for high‐risk neuroblastoma. International Journal of Cancer. 2025. doi:10.1002/ijc.70043

BibTeX
@article{Kushner2025,
  author = {Kushner, Brian H and Basu, Ellen M and Cardenas, Fiorella Iglesias and Kramer, Kim and Modak, Shakeel},
  title = {Rapid COJEC without myeloablative therapy for high‐risk neuroblastoma},
  journal = {International Journal of Cancer},
  year = {2025},
  doi = {10.1002/ijc.70043}
}
Kostenlos starten →